×
About 406 results

ALLMedicine™ Cold Agglutinin Disease Center

Research & Reviews  197 results

How I Treat Cold Agglutinin Disease.
https://doi.org/10.1182/blood.2019003809
Blood Berentsen S

Jan 29th, 2021 - The last decades have seen great progress in the treatment of cold agglutinin disease (CAD). Comparative trials are lacking, and recommendations must be based mainly on nonrandomized trials and will be influenced by personal experience. Herein, cu...

In from the cold: M-protein light chain glycosylation is positively associated with col...
https://doi.org/10.1111/trf.16279
Transfusion Juskewitch JE, Murray JD et. al.

Jan 27th, 2021 - Primary cold agglutinin disease (CAD) is a monoclonal antibody (M-protein) and complement-mediated chronic hemolytic disease process. Antibody glycosylation can play a role in both antibody half-life and complement fixation. Recently, M-protein li...

Pembrolizumab-Induced Cold Agglutinin Disease.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491957
The American Journal of Case Reports; Atiq O, Atiq SO et. al.

Sep 5th, 2020 - BACKGROUND The introduction of immunotherapy in the management of metastatic lung cancer appears to be changing their natural history. Most patients tolerate immunotherapy without any significant adverse events. Nevertheless, a significant number ...

Do temperature and time matter in cold agglutinin disease?
https://doi.org/10.1182/blood.2020006566
Blood Röth A

Jul 23rd, 2020 - Do temperature and time matter in cold agglutinin disease?|2020|Röth A,|

Demographic characteristics, thromboembolism risk, and treatment patterns for patients ...
https://doi.org/10.1007/s12185-020-02899-6
International Journal of Hematology; Kamesaki T, Nishimura JI et. al.

Jul 1st, 2020 - Cold agglutinin disease (CAD) is a rare, complement-mediated autoimmune hemolytic anemia. Patients with CAD in the United States and Europe have an increased incidence of thromboembolism (TE), but comparable information for patients in other regio...

see more →

Guidelines  1 results

FDA grants orphan drug designation to APL-2 for autoimmune hemolytic anemia
https://www.healio.com/hematology-oncology/hematology/news/online/%7B2785cd04-4008-4105-91cc-e82f5573ee6f%7D/fda-grants-orphan-drug-designation-to-apl-2-for-autoimmune-hemolytic-anemia

Feb 4th, 2019 - The FDA granted orphan drug designation to the C3 complement inhibitor APL-2 for the treatment of autoimmune hemolytic anemia. Autoimmune hemolytic anemia refers to both cold agglutinin disease and warm autoimmune hemolytic anemia, which affect a ...

see more →

Clinicaltrials.gov  201 results

How I Treat Cold Agglutinin Disease.
https://doi.org/10.1182/blood.2019003809
Blood Berentsen S

Jan 29th, 2021 - The last decades have seen great progress in the treatment of cold agglutinin disease (CAD). Comparative trials are lacking, and recommendations must be based mainly on nonrandomized trials and will be influenced by personal experience. Herein, cu...

In from the cold: M-protein light chain glycosylation is positively associated with col...
https://doi.org/10.1111/trf.16279
Transfusion Juskewitch JE, Murray JD et. al.

Jan 27th, 2021 - Primary cold agglutinin disease (CAD) is a monoclonal antibody (M-protein) and complement-mediated chronic hemolytic disease process. Antibody glycosylation can play a role in both antibody half-life and complement fixation. Recently, M-protein li...

Pembrolizumab-Induced Cold Agglutinin Disease.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491957
The American Journal of Case Reports; Atiq O, Atiq SO et. al.

Sep 5th, 2020 - BACKGROUND The introduction of immunotherapy in the management of metastatic lung cancer appears to be changing their natural history. Most patients tolerate immunotherapy without any significant adverse events. Nevertheless, a significant number ...

Do temperature and time matter in cold agglutinin disease?
https://doi.org/10.1182/blood.2020006566
Blood Röth A

Jul 23rd, 2020 - Do temperature and time matter in cold agglutinin disease?|2020|Röth A,|

Demographic characteristics, thromboembolism risk, and treatment patterns for patients ...
https://doi.org/10.1007/s12185-020-02899-6
International Journal of Hematology; Kamesaki T, Nishimura JI et. al.

Jul 1st, 2020 - Cold agglutinin disease (CAD) is a rare, complement-mediated autoimmune hemolytic anemia. Patients with CAD in the United States and Europe have an increased incidence of thromboembolism (TE), but comparable information for patients in other regio...

see more →

News  7 results

Sanofi gets priority U.S. FDA review for sutimlimab product
https://www.reuters.com/article/us-sanofi-products/sanofi-gets-priority-u-s-fda-review-for-sutimlimab-product-idUSKBN22Q0JI

May 14th, 2020 - FILE PHOTO: The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24, 2020. REUTERS/Charles Platiau PARIS (Reuters) - French healthcare company Sanofi said on Thursday that the U.S. Food & Drug Administration (FDA) regul...

Sutimlimab boosts hemoglobin, quality of life in cold agglutinin disease
https://www.mdedge.com/hematology-oncology/article/214191/anemia/sutimlimab-boosts-hemoglobin-quality-life-cold-agglutinin?channel=39313
Neil Osterweil

Dec 12th, 2019 - ORLANDO – An investigational selective inhibitor of the complement pathway, sutimlimab, induced rapid and sustained benefits in patients with cold agglutinin disease, a rare autoimmune hemolytic anemia with no currently approved effective therapie.

FDA grants orphan drug designation to APL-2 for autoimmune hemolytic anemia
https://www.healio.com/hematology-oncology/hematology/news/online/%7B2785cd04-4008-4105-91cc-e82f5573ee6f%7D/fda-grants-orphan-drug-designation-to-apl-2-for-autoimmune-hemolytic-anemia

Feb 4th, 2019 - The FDA granted orphan drug designation to the C3 complement inhibitor APL-2 for the treatment of autoimmune hemolytic anemia. Autoimmune hemolytic anemia refers to both cold agglutinin disease and warm autoimmune hemolytic anemia, which affect a ...

Potential treatment on the horizon for cold agglutinin disease
https://www.mdedge.com/hematology-oncology/article/192203/anemia/potential-treatment-horizon-cold-agglutinin-disease
HT Staff

Jan 2nd, 2019 - Red blood cells In a first-in-human trial, sutimlimab rapidly halted hemolysis, corrected anemia, precluded the need for transfusion, and caused no serious adverse effects in patients with cold agglutinin disease. Sutimlimab also “induced clinical.

Drug granted orphan designation for hemolytic anemia
https://www.mdedge.com/hematology-oncology/article/188833/anemia/drug-granted-orphan-designation-hemolytic-anemia
HT Staff

Mar 1st, 2016 - Red blood cells The European Commission (EC) has granted orphan drug designation for TNT009 to treat autoimmune hemolytic anemia, including cold agglutinin disease. TNT009 is a monoclonal antibody that selectively inhibits the classical complement.

see more →